To the Editor The analysis of prescription drug net price growth by Dr Hernandez and colleagues1 has 2 methodological issues that affect the interpretation of results. First, the authors overestimated the increase in discounts provided by drug manufacturers to non-Medicaid payers and underestimated the increase in discounts to Medicaid. Second, their methodology for estimating the mean growth in prices and discounts cannot be linked to drug spending.
Anderson-Cook A, Noda A. Drug Prices, Rebates, and Discounts. JAMA. 2020;324(4):398–399. doi:10.1001/jama.2020.7989
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: